|

Fludrocortisone acetate Clinical Trials

3 actively recruiting trials across 3 locations

Pipeline

Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC3

Indications

  • Cancer3
  • Prostatic Neoplasms, Castration-Resistant1
  • Metastatic Castration-resistant Prostate Cancer, mCRPC1
  • Prostate Cancer Metastatic1
  • Prostatic Neoplasms1

Tucson, Arizona1 trial

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The University of Arizona Cancer Center - North Campus ( Site 0073)

Phase 3

La Jolla, California1 trial

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

UCSD Moores Cancer Center ( Site 0039)

Phase 1/2

Orange, California1 trial

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040)

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.